Recordati Refocuses

Diversification didn't pay off very well for Italy's Recordati Industria Chimica & Farmaceutica SPA. The company's revised growth strategy depends mostly on developing assets it already has, principally its fine chemicals business, and an already-approved calcium antagonist called lercanidipine.